

Expert consultation on prostate cancer screening and early detection in Latin America and the Caribbean

12-13 September 2017
National Cancer Institute of Mexico, Mexico City

AGENDA

Context:

In Latin America and the Caribbean (LAC), prostate cancer is the most common cancer in men over 50 years of age, with approximately 152,000 new cases and 51,000 deaths each year. If measures are not taken, the incidence of prostate cancer in LAC will increase by 84% to 280,000 new cases, while deaths will double to 100,000 by 2030. The Caribbean countries, notably Barbados, Trinidad and Tobago, and Jamaica have the highest prostate cancer rates.

Late stage diagnosis of prostate cancer contributes to the high mortality rates in LAC, however screening and early detection of prostate cancer present a number of challenges. The use of prostate-specific antigen (PSA) remains controversial and the scientific community has not yet reached consensus on population-based prostate cancer screening strategies. As a result, the World Health Organization has not yet developed specific recommendations for prostate cancer screening, although guidance has been developed on the health system requirements for cancer screening and early detection programs.

Many countries have been promoting systematic prostate cancer screening, using the PSA test for the entire male population. However, this approach can lead to over-diagnosis and over-treatment causing more harm than good. More recently, countries such as Canada and the United States have promoted patient-centered strategies for prostate cancer screening, based on individual risk and preferences. These models could serve as examples for other countries in the region to address the prostate cancer problem.

With this background, the Pan American Health Organization (PAHO), in collaboration with the Mexico National Cancer Institute and Mexico National Public Health Institute are convening an expert consultation to review the evidence and experiences on prostate cancer screening, with a view to develop future guidance appropriate for the context of Latin America and the Caribbean.

Objectives:

1. Review available scientific information and evidence on methods and strategies for prostate cancer screening and early detection.
2. Discuss the existing national guidelines on prostate cancer screening and early detection.
3. Exchange experiences and learn about best practices for prostate cancer screening and early detection in the Americas.

Tuesday, September 12, 2017	
8:30am	PARTICIPANT REGISTRATION
9:00am	OPENING REMARKS <i>Miguel Malo</i> , PAHO/WHO country office of Mexico <i>Abelardo Meneses</i> , Director, National Cancer Institute of Mexico (INCan)
9:10am	OVERVIEW OF THE MEETING OBJECTIVES <i>Silvana Luciani</i> , PAHO/WHO <i>Alejandro Mohar</i> , INCan, <i>Fernando Gabilondo</i> , National Institute of Medical Sciences and Nutrition Salvador Zubirán <i>Martin Lajous</i> , National Institute of Public Health of Mexico (INSP)
9:30am	SESSION 1: PROSTATE CANCER IN LATIN AMERICA AND THE CARIBBEAN The burden of prostate cancer in the region, in the context of the Global Burden of Disease Project (GBD). <i>Héctor Lamadrid</i> , National Institute of Public Health of Mexico Questions and answers
10:00am	SESSION 2: SCIENTIFIC EVIDENCE ON STRATEGIES FOR EARLY DETECTION OF PROSTATE CANCER <i>Moderator: Miguel Ángel Jiménez</i> , INCan The role of prostate specific antigen (PSA) testing in screening and early detection of prostate cancer. <i>Matthew Cooperberg</i> , University of California, San Francisco Questions and answers
11:00am	COFFEE BREAK
11:30am	SESSION 3: TO SCREEN OR NOT TO SCREEN, CONCLUSIONS OF NATIONAL GUIDELINES <i>Moderator: Luisa Torres-Sánchez</i> , INSP U.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation <i>Alex Krist</i> , US Preventive Services Task Force Experiences in implementing Canada's prostate cancer screening guidelines <i>James Dickinson</i> , Canadian Task Force on Preventive Health Care Mexico case study: Timely detection of prostate cancer based on the new Mexican Norms <i>Fernando Gabilondo</i> , Mexico National Institute of Medical Sciences and Nutrition Questions and answers
1:00pm	LUNCH

2:00pm	<p>SESSION 4: SHARING EXPERIENCES ABOUT PROSTATE CANCER SCREENING Moderated discussion on experiences in Latin America and the Caribbean</p> <p><i>Moderator:</i> Alejandro Mohar, INCan</p> <p><i>Panelists:</i> BRAZIL: Alexander Dias, National Cancer Institute CHILE: María Inés Romero, Ministry of Health JAMAICA: Tamu Davidson-Sadler, Ministry of Health PANAMÁ: Armando de Gracia, National Oncologic Institute TRINIDAD & TOBAGO: Lester Goetz, University of the West Indies</p> <p>Questions and answers</p>
3:30pm	COFFEE BREAK
4:00pm	<p>SESSION 5: Structured conversation. Perspectives on the Use of PSA testing in Latin America and the Caribbean</p> <p><i>Moderator:</i> Martín Lajous</p> <p><i>Discussion starter:</i> Mathew Cooperberg</p>
5:30pm	ADJOURN AND SOCIAL EVENT

Wednesday, September 13, 2017	
9:30am	REVIEW of the discussion and results from the first day
9:45am	<p>SESSION 6: Health System Considerations for Prostate Cancer Screening Programs</p> <p><i>Discussion starter:</i> Octavio Gómez-Dantés, INSP <i>Moderator:</i> Sebastián García-Saisó, Secretaría de Salud</p> <p>Moderate and structured discussion to identify the necessary considerations in the implementation of strategies for the timely diagnosis of prostate cancer:</p> <ul style="list-style-type: none"> • Which strategies, based on the successful experiences shown on day 1, are applicable to LAC countries? • What are the criteria to consider before introducing and implementing a prostate cancer screening program? • What processes should be followed to reach consensus on recommendations for screening for prostate cancer in LAC? • What health service capacity is needed to ensure appropriate follow up diagnosis and treatment for prostate cancer? • Is it feasible to establish similar approaches with greater patient participation in the decision of being screened in LAC countries and especially in areas with limited resources?
11:00am	CAFÉ
11:30am	SESSION 6: Discussion (cont'd)
12:00pm	<p>CONCLUSIONS and NEXT STEPS</p> <p><i>Moderator:</i> Silvana Luciani</p> <p>Discussion and agreements to improve prostate cancer screening in LAC</p>
12:30pm	END OF THE REGIONAL MEETING